{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:23:47Z","timestamp":1793762627505,"version":"4.6.1"},"reference-count":48,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T00:00:00Z","timestamp":1256601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:p> <jats:bold>PENTA Guidelines aim to provide practical recommendations for treating children with HIV infection in Europe<\/jats:bold>. Changes to guidance since 2004 have been informed by new evidence and by expectations of better outcomes following the ongoing success of antiretroviral therapy (ART). Participation in PENTA trials of simplifying treatment is encouraged. The main changes are in the following sections:<\/jats:p><jats:p> <jats:italic>\u2018When to start ART\u2019<\/jats:italic>: Treatment is recommended for all infants, and at higher CD4 cell counts and percentages in older children, in line with changes to adult guidelines. The number of age bands has been reduced to simplify and harmonize with other paediatric guidelines. Greater emphasis is placed on CD4 cell count in children over 5 years, and guidance is provided where CD4% and CD4 criteria differ.<\/jats:p><jats:p> <jats:italic>\u2018What to start with\u2019<\/jats:italic>: A three\u2010drug regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) with either a nonnucleoside reverse transcriptase inhibitor (NNRTI) or a boosted protease inhibitor (PI) remains the first choice combination. Lamivudine and abacavir are the NRTI backbone of choice for most children, based on long\u2010term follow\u2010up in the PENTA 5 trial. Stavudine is no longer recommended. Whether to start with an NNRTI or PI remains unclear, but PENPACT 1 trial results in 2009 may help to inform this. All PIs should be ritonavir boosted.<\/jats:p><jats:p> <jats:italic>Recommendations on use of resistance testing, therapeutic drug monitoring and HLA testing<\/jats:italic> draw from data in adults and from European paediatric cohort studies.<\/jats:p><jats:p>Recently updated US and WHO paediatric guidelines provide more detailed review of the evidence base. Differences between guidelines are highlighted and explained.<\/jats:p>","DOI":"10.1111\/j.1468-1293.2009.00759.x","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T06:49:46Z","timestamp":1256626186000},"page":"591-613","source":"Crossref","is-referenced-by-count":111,"title":["PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV\u20101 infection"],"prefix":"10.1111","volume":"10","author":[{"name":"PENTA Steering Committee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,27]]},"reference":[{"key":"e_1_2_17_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2004.00227.x"},{"key":"e_1_2_17_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00636.x"},{"key":"e_1_2_17_4_2","volume-title":"Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach","author":"World Health Organization.","year":"2007"},{"key":"e_1_2_17_5_2","volume-title":"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection","author":"Working Group on Antiretroviral Therapy and Medical Management of HIV\u2010Infected Children","year":"2008"},{"key":"e_1_2_17_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199706010-00004"},{"key":"e_1_2_17_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199509000-00001"},{"key":"e_1_2_17_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200302010-00011"},{"key":"e_1_2_17_9_2","first-page":"918","article-title":"Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996\u20132006","volume":"45","author":"Judd A","year":"2007","journal-title":"planning for teenage and adult care"},{"issue":"12","key":"e_1_2_17_10_2","first-page":"1","article-title":"1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age","volume":"43","author":"Centers for Disease Control and Prevention.","year":"1994","journal-title":"Morbid Mortal Wkly Rep"},{"key":"e_1_2_17_11_2","volume-title":"WHO Case Definitions of HIV for Surveillance, and Revised Clinical Staging and Immunological Classification of HIV Related Disease in Adults and Children","author":"World Health Organization.","year":"2006"},{"key":"e_1_2_17_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706135"},{"key":"e_1_2_17_13_2","first-page":"1865","article-title":"Co\u2010trimoxazole as prophylaxis against opportunistic infections in HIV\u2010infected Zambian children (CHAP)","volume":"364","author":"Chintu C","year":"2004","journal-title":"a double-blind randomised placebo-controlled trial"},{"key":"e_1_2_17_14_2","volume-title":"Guidelines on Co\u2010Trimoxazole Prophylaxis for HIV\u2010related Infections Among Children, Adolescents and Adults: Recommendations for a Public Health Approach","author":"World Health Organization.","year":"2006"},{"key":"e_1_2_17_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6926.437"},{"key":"e_1_2_17_16_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-1847"},{"key":"e_1_2_17_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000194795.20928.2b"},{"key":"e_1_2_17_18_2","volume-title":"Treating Opportunistic Infections in HIV\u2010Infected Children","author":"Chakraborty R","year":"2006"},{"key":"e_1_2_17_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800971"},{"key":"e_1_2_17_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328326ca37"},{"key":"e_1_2_17_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/524686"},{"key":"e_1_2_17_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062360"},{"key":"e_1_2_17_23_2","first-page":"1605","article-title":"Short\u2010term risk of disease progression in HIV\u20101\u2010infected children receiving no antiretroviral therapy or zidovudine monotherapy","volume":"362","author":"HIV Paediatric Prognostic Markers Collaborative Study Group.","year":"2003","journal-title":"a meta-analysis"},{"key":"e_1_2_17_24_2","first-page":"1868","article-title":"Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV\u2010infected children","volume":"366","author":"HIV Paediatric Prognostic Markers Collaborative Study Group.","year":"2005","journal-title":"a meta-analysis of longitudinal data"},{"key":"e_1_2_17_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000232237.20792.68"},{"key":"e_1_2_17_26_2","unstructured":"EmerySfor theSMART Study Group INSIGHT.Major clinical outcomes in patients not treated with antiretroviral therapy at baseline in SMART: a rationale for a trial to examine early treatment of HIV disease.4th IAS Conference on HIV Pathogenesis Treatment and Prevention. Sydney Australia July 2007 [Abstract WEPEB018]."},{"key":"e_1_2_17_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/29.3.573"},{"key":"e_1_2_17_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000214994.44346.d3"},{"key":"e_1_2_17_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32827038bf"},{"key":"e_1_2_17_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.10.756"},{"key":"e_1_2_17_31_2","first-page":"2447","article-title":"Increased risk of lipoatrophy under stavudine in HIV\u20101\u2010infected patients","volume":"16","author":"Joly V","year":"2002","journal-title":"results of a substudy from a comparative trial"},{"key":"e_1_2_17_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3280e087e7"},{"key":"e_1_2_17_33_2","first-page":"239","article-title":"Plasma pharmacokinetics of once\u2010 vs. twice\u2010daily lamivudine and abacavir","volume":"10","author":"Bergshoeff A","year":"2005","journal-title":"simplification of combination treatment in HIV-1-infected children (PENTA-13)"},{"key":"e_1_2_17_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000222415.40563.d4"},{"key":"e_1_2_17_35_2","first-page":"1417","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV\u2010infected patients enrolled in the D:A:D study","volume":"371","author":"Sabin CA","year":"2008","journal-title":"a multi-cohort collaboration"},{"key":"e_1_2_17_36_2","unstructured":"BensonC RibaudoH ZhengEet al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001.16th Conference on Retroviruses and Opportunistic Infections. Montreal Canada February 2009 [Abstract 721]."},{"key":"e_1_2_17_37_2","unstructured":"ReissP.Abacavir and Cardiovascular Risk.16th Conference on Retroviruses and Opportunistic Infections. Montr\u00e9al Canada February 2009 [Abstract 152]."},{"key":"e_1_2_17_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032706"},{"key":"e_1_2_17_39_2","first-page":"1253","article-title":"Comparison of first\u2010line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine","volume":"363","author":"Van Leth F","year":"2004","journal-title":"a randomised open-label trial, the 2NN Study"},{"key":"e_1_2_17_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200307250-00008"},{"key":"e_1_2_17_41_2","first-page":"883","article-title":"Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor\u2010na\u00efve, nonnucleoside reverse transcriptase inhibitor\u2010experienced patients","volume":"9","author":"Ruxrungtham K","year":"2008","journal-title":"Study TMC125-C227"},{"key":"e_1_2_17_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm436"},{"key":"e_1_2_17_43_2","first-page":"e1371","article-title":"Adherence to antiretroviral therapy for pediatric HIV infection","volume":"119","author":"Simoni JM","year":"2007","journal-title":"a qualitative systematic review with recommendations for research and clinical management"},{"key":"e_1_2_17_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200301000-00018"},{"key":"e_1_2_17_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328133f29c"},{"issue":"1","key":"e_1_2_17_46_2","first-page":"O21","article-title":"Treatment interruption in children with chronic HIV\u2010infection","volume":"11","author":"Gibb D","year":"2008","journal-title":"the results of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial"},{"key":"e_1_2_17_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/587657"},{"key":"e_1_2_17_48_2","unstructured":"LeeKJ LyallEGH WalkerASet al. Wide disparity in switch to second\u2010line therapy in HIV\u2010infected children in CHIPS.8th International Congress on Drug Therapy in HIV Infection. Glasgow UK November 2006 [Abstract PL 2.4]."},{"key":"e_1_2_17_49_2","first-page":"949","article-title":"Transient viral load increases in HIV\u2010infected children in the UK and Ireland","volume":"12","author":"Lee KJ","year":"2007","journal-title":"what do they mean?"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00759.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00759.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:37:09Z","timestamp":1696876629000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00759.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,27]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00759.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00759.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,27]]}}}